News

Immunophotonics Partners with Johnson & Johnson

St. Louis cancer drug startup Immunophotonics Inc. will pursue expansion of its lead drug candidate through a partnership with the innovation arm of pharmaceutical giant Johnson & Johnson. The clinical-stage startup has formed a research collaboration with Johnson & Johnson Enterprise Innovation Inc. (JJEI) to study its lead drug candidate, IP-001, being used in conjunction with radiation therapy to treat tumors…